Brief: Innovation Pharmaceuticals Announces Publication Of Peer-Reviewed Scientific Article In Journal Viruses On Anti-Sars-Cov-2 Properties Of Brilacidin
02/03/2021 14:19
March 2 (Reuters) - Innovation Pharmaceuticals Inc
IPIX.PK :
* INNOVATION PHARMACEUTICALS ANNOUNCES PUBLICATION OF
PEER-REVIEWED SCIENTIFIC ARTICLE IN JOURNAL VIRUSES ON
ANTI-SARS-COV-2 PROPERTIES OF BRILACIDIN
* INNOVATION PHARMACEUTICALS INC - BRILACIDIN IS CURRENTLY
BEING
EVALUATED IN A PHASE 2 CLINICAL TRIAL IN HOSPITALIZED COVID-19
PATIENTS
Source text for Eikon: ID:nGNX7vC4JV
Further company coverage: IPIX.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innovation Pharmaceuticals
See all newsBrief: Innovation Pharmaceuticals Announces New Milestone At Beamed On Track To File 510(K) Submission To FDA In Q2 2024
Brief: Innovation Pharmaceuticals Provides Update On US Patent Applications Covering Use Of Brilacidin In Inflammatory Bowel Diseases, Coronaviruses And Fungal Diseases
Brief: Innovation Pharma Reports Enrollment In Phase 2 Trial Of Brilacidin For COVID-19 Tops 70%
Brief: Innovation Pharma Surpasses 50% Enrollment In Phase 2 Clinical Trial Of Brilacidin For COVID-19
Brief: Innovation Pharma Completes Interim Safety Data Review